Search Results
Your search for this matches 25378 pages
Showing 23951 - 24000FDA Approves Nine-Valent HPV Vaccine for Prevention of Certain Cancers Caused by Five Additional Types of HPV
The U.S. Food and Drug Administration (FDA) today approved recombinant nine-valent human papillomavirus vaccine (Gardasil 9) for the prevention of certain diseases caused by nine types of HPV. The nine-valent vaccine covers five more HPV types than the previously approved quadrivalent vaccine...
SABCS 2014: High Tumor Immune Cell Levels May Identify HER2-Positive Breast Cancer Patients Who Might Benefit From Chemotherapy Alone
Women with HER2-positive breast cancer who had high levels of immune cells in their tumors had a decreased risk of cancer recurrence after treatment with chemotherapy alone compared with their counterparts who had low levels of tumor-infiltrating immune cells, according to data presented at the...
SABCS 2014: Pembrolizumab Holds Promise in Breast Cancer, Early Studies Suggest
Single-agent treatment with the immunotherapy drug pembrolizumab (Keytruda) produced a “signal of activity” and led to some durable response, in patients with metastatic triple-negative breast cancer, Rita Nanda, MD, of the University of Chicago, reported at the 2014 San Antonio Breast...
SABCS 2014: PI3K Inhibition With Pictilisib in Hormone Receptor–Positive Breast Cancer Not Ready for Prime Time
Interest is high in studying the PI3K pathway in hormone receptor–positive breast cancer, but it is not clear which of the PI3K inhibitors under development—if any—will be a “home run.” Adding the pan-class I selective PI3K inhibitor pictilisib to fulvestrant...
ASH 2014: Pracinostat Combination Shows Significant Clinical Activity in Phase II Study of Newly Diagnosed Acute Myeloid Leukemia
In a phase II study, the histone deacetylase inhibitor pracinostat demonstrated significant clinical activity in combination with azacitadine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients were presented at the 56th American Society of ...
ASH 2014: Common Genetic Variations May Contribute to Treatment-Related Cognitive Problems in Children With Leukemia
Common variations in four genes related to brain inflammation or cells′ response to damage from oxidation may contribute to the problems with memory, learning, and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study presented at the...
ASH 2014: T-Cell Acute Lymphoblastic Leukemia Outcomes Excellent, Even for 'Poor-Risk' Group
Outcomes in children with T-cell acute lymphoblastic leukemia (ALL), which has traditionally been considered a poor-prognosis cancer, are better than expected, even for the early thymic precursor (ETP) phenotype, according to investigators from the Children’s Oncology Group (COG) who...
ASH 2014: High Hopes for AG-221 in Advanced Leukemia
Although the data are preliminary, single-agent AG-221 therapy targeted to the IDH2 mutation holds great promise as a nonchemotherapy approach for the treatment of advanced hematologic malignancies, including relapsed/refractory acute myelogenous leukemia (AML) and untreated AML. The findings were...
Daniel F. Hayes, MD, FASCO, Elected ASCO President for 2016-2017 Term
Daniel F. Hayes, MD, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2015. “I'm honored to be elected incoming President of...
ASH 2014: Combination Therapy Shown to Be Effective for Patients With Myelodysplastic Syndrome and AML
A phase II study investigating the potential of the drugs azacitidine and lenalidomide (Revlimid) demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia (AML). The...
CDK7 Inhibitor Effective in Reducing Small Cell Lung Cancer in Preclinical Study
Although small cell lung cancer is an aggressive disease with a high mortality rate, in contrast to other lung carcinomas, there has not been significant progress in the development of therapies for the disease in more than 3 decades. Now, researchers using a high-throughput cellular screen of a...
ASH 2014: CD19-Directed CAR T-Cell Therapy Yields High Rate of Durable Remissions in Pediatric Acute Lymphoblastic Leukemia
As more experience is gained with the use of genetically engineered chimeric antigen receptor (CAR) T cells in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the data continue to be highly encouraging. To date, 36 of 39 pediatric ALL patients (92%) treated with...
ASH 2014: Ibrutinib Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, ibrutinib (Imbruvica) demonstrated antitumor activity both as a single agent and in combination with dexamethasone in heavily pretreated patients with relapsed or relapsed/refractory...
ASH 2014: PD-1 Blockade Moves Into Hematology
The promise of the programmed death receptor-1 (PD-1) inhibitors seen in solid tumors, especially melanoma, may hold true for at least one hematologic malignancy, according to studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. At a press briefing,...
ASH 2014: Post-Transplant Brentuximab Vedotin Improves Progression-Free Survival in Hodgkin Lymphoma Patients
In Hodgkin lymphoma patients at risk for disease progression following autologous stem cell transplant, early consolidation post-transplant with brentuximab vedotin (Adcetris) significantly improved progression-free survival compared with placebo in the phase III AETHERA trial. The findings were...
ASH 2014: HIV-Related Lymphoma Can Be Safely Treated With Autologous Hematopoietic Cell Transplant
Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
ASH 2014: Strong Showing for Anti-CD38 Monoclonal Antibodies in Myeloma
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next blockbuster agents in multiple myeloma, experts in this malignancy predicted at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. Anti-CD38 antibodies target multiple myeloma...
ASH 2014: Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
The phase III global ASPIRE trial documented an “unprecedented” duration of remission in relapsed multiple myeloma patients receiving carfilzomib (Kyprolis) plus a standard-of-care doublet, according to A. Keith Stewart, MD, of the Mayo Clinic in Scottsdale, Arizona, who presented the...
‘Wound Response’ of Cancer Stem Cells May Explain Chemoresistance in Bladder Cancer
A novel mechanism—similar to how normal tissue stem cells respond to wounding—might explain why bladder cancer stem cells actively contribute to chemoresistance after multiple cycles of chemotherapy drug treatment. Targeting this “wound response” of cancer stem cells can...
Telomere Length Genes Are Associated With Melanoma Risk
Longer telomeres have been associated with increased risk of melanoma. In a GenoMEL Consortium genome-wide association study reported in the Journal of the National Cancer Institute, Iles et al found that several single-nucleotide polymorphisms (SNPs) previously associated with leukocyte telomere...
No Disease-Free Survival Differences Among Doxorubicin/Cyclophosphamide Plus Paclitaxel Regimens in High-Risk Early-Stage Breast Cancer
In the phase III SWOG S0221 trial reported in the Journal of Clinical Oncology, Budd et al found no differences in disease-free survival among four different doxorubicin/cyclophosphamide plus paclitaxel regimens in patients with node-positive or high-risk node-negative breast cancer. A subgroup...
FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) today approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too...
Effect of Computer-Aided Detection in Mammography Screening on Cost and DCIS Diagnosis in Medicare Population
In a study reported in a research letter in JAMA Surgery, Fenton et al found that a sizable proportion of ductal carcinoma in situ (DCIS) diagnoses are attributable to computer-aided detection in mammography screening in the Medicare population and that use of computer-aided detection in this...
Ixazomib Receives Breakthrough Therapy Designation for Relapsed or Refractory Systemic Light-Chain Amyloidosis
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to Takeda Pharmaceuticals’ investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain amyloidosis. This is the first proteasome inhibitor...
FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
Risk-Based Screening Misses Over 75% of Invasive Breast Cancers in Women in Their 40s
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented today at RSNA 2014, the annual meeting of the...
Bisphosphonates May Block the Development of HER-Driven Tumors, Preventing Breast, Lung, and Colon Cancers
Two studies have found that bisphosphonates may be effective in preventing certain cancers—including lung, breast, and colon—by blocking abnormal growth signals passed through HER family receptors. The studies suggest that bisphosphonates, the most commonly prescribed medications for...
3D Mammography Improves Cancer Detection in Dense Breasts
A new study presented at RSNA 2014, the annual meeting of the Radiological Society of North America, has found that digital breast tomosynthesis, also known as three-dimensional (3D) mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women ...
CONCORD-2 Study Reveals Wide Variability in Global Cancer Survival Rates
As reported in The Lancet by Allemani et al, the CONCORD-2 study of global cancer survival indicates improvements in survival in many countries in colorectal, breast, and prostate cancers, persistent poor outcomes in lung and liver cancers, and wide variability in survival in many cancers. The...
DNA Vaccine Targeting Mammaglobin-A Produces Robust Immune Response in Metastatic Breast Cancer
In a phase I study, a DNA vaccine targeting the breast cancer–associated antigen mammaglobin-A (MAM-A) was found to be safe and effective in eliciting immune responses in women with metastatic breast cancer. Preliminary evidence also suggests that the vaccine improved progression-free...
Despite Popularity of Alternative Medicine, Most U.S. Oncologists Do Not Discuss Herb and Supplement Use With Their Patients
Available data indicate that a majority of cancer patients use complementary and alternative medicine. In a study reported in the Journal of Clinical Oncology, Lee et al found that oncologists responding to a survey on herb and supplement use did not discuss herb and supplement use with most of...
FDG-PET Predicts Complete Response to Neoadjuvant Trastuzumab/Docetaxel in HER2-Positive Breast Cancer
In the French phase II AVATAXHER trial reported in The Lancet Oncology, Coudert et al found that 18F–fluorodeoxyglucose (FDG) positron-emission tomography (PET) predicted complete response to trastuzumab (Herceptin)/docetaxel neoadjuvant therapy and that adding bevacizumab (Avastin) in...
More Than 40% of U.S. Women Have Mammographically Dense Breasts
In a study reported in the Journal of the National Cancer Institute, Sprague et al found that more than 40% of U.S. women have mammographically dense breasts, with the prevalence being inversely proportional to age and body mass index (BMI). As noted by the authors: “National legislation is...
Addition of Vosaroxin to Cytarabine Demonstrates Antileukemic Activity in Relapsed or Refractory Acute Myeloid Leukemia
In a phase Ib/II study of patients with relapsed or refractory acute myeloid leukemia (AML), the addition of vosaroxin to cytarabine demonstrated antileukemic activity and an acceptable risk-benefit profile, according to a study by Lancet et al in Haematologica. Based on the findings from this...
Adult Survivors of Retinoblastoma Experience Few Cognitive or Social Setbacks
Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment, according to a study by Brinkman et al published in Cancer. The findings offer good news for patients, but the...
High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...
Improved Overall Survival in Metastatic Melanoma With First-Line Dabrafenib Plus Trametinib
In a phase III study reported in The New England Journal of Medicine, Robert et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor trametinib (Mekinist) significantly improved overall survival compared with the BRAF inhibitor vemurafenib (Zelboraf) in...
Two- vs One-Unit Cord Blood Transplantation Does Not Improve 1-Year Overall Survival in Children and Adolescents With Hematologic Cancers
In a phase III trial reported in The New England Journal of Medicine, Wagner et al found that use of two units vs one unit of umbilical cord blood in hematopoietic stem cell transplantation did not improve 1-year overall survival in children and adolescents with hematologic cancers. Use of...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
As reported in the Journal of the National Cancer Institute, Mitra et al have identified a novel genomic-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer. Use of the signature could help guide selection of patients for adjuvant therapy...
No Overall Survival Difference for Amrubicin vs Topotecan in Second-Line Treatment of Small Cell Lung Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Pawel et al found no difference in overall survival with amrubicin vs topotecan as second-line therapy in patients with first-line sensitive or refractory small cell lung cancer. An overall survival benefit of amrubicin was observed ...
Exposure to Hookah Smoke Doubles Benzene Uptake, Potentially Increasing Risk for Leukemia
Findings from a new study show that hookah smokers and nonsmokers exposed to hookah (or waterpipe) secondhand tobacco smoke at social events in hookah lounges and in private homes had significant increases in uptake of benzene, a leukemogen that causes lymphohematopoietic cancers, especially acute...
FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties
The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate (Hysingla ER), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product...
Researchers Identify Biomarker of Response to New Ovarian Cancer Drug
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
About 25% of Patients Undergoing Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery
“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online in JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility...
Nivolumab Improves Overall and Progression-Free Survival vs Dacarbazine in Previously Untreated Advanced Melanoma Without BRAF Mutation
In a phase III trial reported in The New England Journal of Medicine, Robert et al found that the PD-1 immune-checkpoint–inhibitor antibody nivolumab significantly increased overall survival, progression-free survival, and objective response rate compared with dacarbazine in patients with...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...
